The brokers aren’t listening27 May 2022 10:35
I have read the Jefferies and Berenberg reports. Both seem ignorant of the important point, made in both of the CEO webinars, that FDA approval allows AGL to sell the Parsortix system as a product, not just a service. This should greatly enhance the revenue and profit stream once reimbursement codes are assigned. Which hospital wouldn’t want this product given its lower cost and efficacy ? Market size is hard to estimate, I agree, but very little mention is made of this in the broker reports. Is it just me, or have other posters noticed this same omission ?